BR112022011284A2 - Composição tópica e métodos de medição da capacidade de resfriamento de uma composição tópica - Google Patents

Composição tópica e métodos de medição da capacidade de resfriamento de uma composição tópica

Info

Publication number
BR112022011284A2
BR112022011284A2 BR112022011284A BR112022011284A BR112022011284A2 BR 112022011284 A2 BR112022011284 A2 BR 112022011284A2 BR 112022011284 A BR112022011284 A BR 112022011284A BR 112022011284 A BR112022011284 A BR 112022011284A BR 112022011284 A2 BR112022011284 A2 BR 112022011284A2
Authority
BR
Brazil
Prior art keywords
composition
topical composition
cooling capacity
measuring
methods
Prior art date
Application number
BR112022011284A
Other languages
English (en)
Inventor
Davis Adrian
Original Assignee
Futura Medical Developments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1918039.7A external-priority patent/GB201918039D0/en
Priority claimed from GBGB2015404.3A external-priority patent/GB202015404D0/en
Application filed by Futura Medical Developments Ltd filed Critical Futura Medical Developments Ltd
Publication of BR112022011284A2 publication Critical patent/BR112022011284A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00—Investigating or analyzing materials by the use of thermal means
    • G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
    • G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
    • G01N25/4846—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00—Investigating or analyzing materials by the use of thermal means
    • G01N25/56—Investigating or analyzing materials by the use of thermal means by investigating moisture content
    • G01N25/58—Investigating or analyzing materials by the use of thermal means by investigating moisture content by measuring changes of properties of the material due to heat, cold or expansion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Combustion & Propulsion (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

COMPOSIÇÃO TÓPICA E MÉTODOS DE MEDIÇÃO DA CAPACIDADE DE RESFRIAMENTO DE UMA COMPOSIÇÃO TÓPICA. É provida uma composição para aplicação tópica no pênis para o tratamento de disfunção erétil, a composição sendo livre de trinitrato de glicerila (GTN), sildenafila e um inibidor de acetilcolinesterase e compreendendo solventes voláteis e não voláteis, os solventes voláteis compreendendo um álcool e água e os solventes não voláteis compreendendo um álcool poli-hídrico e um glicol. Preferivelmente, a composição não contém nenhum ingrediente farmaceuticamente ativo para o tratamento da disfunção erétil. Também é provido um método para determinar a capacidade de resfriamento de uma composição de teste, tal como a composição descrita acima.
BR112022011284A 2019-12-09 2020-10-22 Composição tópica e métodos de medição da capacidade de resfriamento de uma composição tópica BR112022011284A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1918039.7A GB201918039D0 (en) 2019-12-09 2019-12-09 Topical composition
GBGB2015404.3A GB202015404D0 (en) 2020-09-29 2020-09-29 Topical composition
PCT/GB2020/052660 WO2021116651A1 (en) 2019-12-09 2020-10-22 Topical composition and methods of measuring the cooling abaility of a topical composition

Publications (1)

Publication Number Publication Date
BR112022011284A2 true BR112022011284A2 (pt) 2022-09-06

Family

ID=73040144

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011284A BR112022011284A2 (pt) 2019-12-09 2020-10-22 Composição tópica e métodos de medição da capacidade de resfriamento de uma composição tópica

Country Status (15)

Country Link
US (1) US20230022570A1 (pt)
EP (2) EP3934624B1 (pt)
KR (1) KR20220124712A (pt)
CN (1) CN115003278A (pt)
AU (1) AU2020401440A1 (pt)
BR (1) BR112022011284A2 (pt)
CA (1) CA3160206A1 (pt)
DK (1) DK3934624T3 (pt)
ES (1) ES2978421T3 (pt)
FI (1) FI3934624T3 (pt)
MX (1) MX2022007009A (pt)
PL (1) PL3934624T3 (pt)
PT (1) PT3934624T (pt)
TW (1) TW202135785A (pt)
WO (1) WO2021116651A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117618335B (zh) * 2023-12-27 2024-08-20 江苏澳德智科医疗科技有限公司 一种功能凝胶及其制备方法与应用
CN118576540A (zh) * 2024-07-30 2024-09-03 杭州启真求实科技有限公司 一种用于男性勃起障碍外用的组合物凝胶及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2716739B2 (ja) * 1988-07-26 1998-02-18 インデナ エス．ピー．エイ 血管運動作用を有する化粧用組成物
US5093133A (en) * 1990-01-24 1992-03-03 Mcneil-Ppc, Inc. Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6435710B1 (en) * 1998-08-26 2002-08-20 Fauske & Associates, Inc. Foam detector apparatus and method
GB0602224D0 (en) * 2006-02-03 2006-03-15 Futura Medical Dev Ltd Composition for promoting vascular smooth muscle relaxation
RU2342923C1 (ru) * 2007-07-26 2009-01-10 Общество с ограниченной ответственностью "Бентус лаборатории" Дезинфицирующее антисептическое средство для обработки рук с увлажняющим эффектом (варианты)
US20090318510A1 (en) * 2008-06-24 2009-12-24 Glycobiosciences, Inc. Topical drug delivery system
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
WO2010044094A2 (en) 2008-09-03 2010-04-22 Krishna Radharaman Agarwal A topical composition for the treatment of erectile dysfunction
US20140227342A1 (en) 2013-02-08 2014-08-14 Michael Farber Acetylcholinesterase inhibitor composition for sexual use
CN106659643B (zh) * 2014-04-21 2020-06-19 阿克拉瑞斯治疗股份有限公司 过氧化物制剂及使用过氧化物制剂的方法和施加器
GB201609968D0 (en) * 2016-06-07 2016-07-20 Futura Medical Dev Ltd Topical pharmaceutical formulation
GB201713160D0 (en) 2017-08-16 2017-09-27 Futura Medical Dev Ltd Topical composition
EP3801460A2 (en) * 2018-06-01 2021-04-14 Tavanta Therapeutics Hungary Incorporated Topical amlodipine salts for the treatment of anorectal diseases

Also Published As

Publication number Publication date
TW202135785A (zh) 2021-10-01
KR20220124712A (ko) 2022-09-14
CA3160206A1 (en) 2021-06-17
PL3934624T3 (pl) 2024-07-08
MX2022007009A (es) 2022-08-25
AU2020401440A1 (en) 2022-06-16
WO2021116651A1 (en) 2021-06-17
EP3934624B1 (en) 2024-03-13
PT3934624T (pt) 2024-04-23
FI3934624T3 (fi) 2024-05-24
EP4342494A3 (en) 2024-06-05
EP3934624A1 (en) 2022-01-12
ES2978421T3 (es) 2024-09-12
US20230022570A1 (en) 2023-01-26
EP4342494A2 (en) 2024-03-27
CN115003278A (zh) 2022-09-02
DK3934624T3 (da) 2024-06-10

Similar Documents

Publication Publication Date Title
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CL2022000751A1 (es) Inhibidores de la fosfatasa shp2 y métodos para su uso (divisional de la solicitud no. 202002419)
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
CL2020002866A1 (es) Compuestos de heteroaril tetracíclicos
CO2022015638A2 (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
ECSP22052564A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
ECSP23057264A (es) Inhibidores de cdk2 y métodos de uso de los mismos
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
BR112022011284A2 (pt) Composição tópica e métodos de medição da capacidade de resfriamento de uma composição tópica
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA202192322A1 (ru) Фармацевтические составы
CO2020007044A2 (es) Derivados de pirrol como inhibidores de acc
CL2017001913A1 (es) Composición tópica curativa
EA202191188A1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
EA201990501A1 (ru) Фармацевтическая композиция
EA202190261A1 (ru) Топические маслянистые композиции
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]